Boston Scientific (NYSE:BSX) Price Target Cut to $87.00 by Analysts at Citigroup

Boston Scientific (NYSE:BSX) had its price target decreased by research analysts at Citigroup from $94.00 to $87.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Citigroup’s target price would indicate a potential upside of 40.85% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Stifel Nicolaus reduced their target price on shares of Boston Scientific from $110.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, March 20th. Truist Financial reduced their target price on shares of Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. The Goldman Sachs Group reduced their target price on shares of Boston Scientific from $98.00 to $93.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $104.05.

Boston Scientific Stock Down 1.3%

BSX traded down $0.82 on Tuesday, hitting $61.77. 9,001,235 shares of the company were exchanged, compared to its average volume of 15,807,031. Boston Scientific has a twelve month low of $60.90 and a twelve month high of $109.50. The company has a market cap of $91.80 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a 50-day moving average price of $73.99 and a two-hundred day moving average price of $89.01.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts predict that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rockefeller Capital Management L.P. lifted its holdings in shares of Boston Scientific by 70.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 595,938 shares of the medical equipment provider’s stock valued at $56,823,000 after purchasing an additional 247,097 shares during the last quarter. Bank of New Hampshire lifted its holdings in shares of Boston Scientific by 2.4% in the 4th quarter. Bank of New Hampshire now owns 22,159 shares of the medical equipment provider’s stock valued at $2,113,000 after purchasing an additional 523 shares during the last quarter. World Investment Advisors lifted its holdings in shares of Boston Scientific by 2.2% in the 4th quarter. World Investment Advisors now owns 19,365 shares of the medical equipment provider’s stock valued at $1,846,000 after purchasing an additional 411 shares during the last quarter. Farmers National Bank purchased a new stake in shares of Boston Scientific in the 4th quarter valued at about $204,000. Finally, Corient Private Wealth LLC lifted its holdings in shares of Boston Scientific by 2.6% in the 4th quarter. Corient Private Wealth LLC now owns 224,554 shares of the medical equipment provider’s stock valued at $21,437,000 after purchasing an additional 5,756 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterates an Outperform on BSX after the CHAMPION‑AF readout met primary safety and efficacy endpoints presented at ACC; analyst Mike Kratky kept a constructive view despite some data nuances, supporting the stock’s clinical credibility in electrophysiology. Read More.
• Positive Sentiment: Boston Scientific completed the acquisition of Valencia Technologies, a move that strengthens its position vs. Medtronic in an under‑penetrated market and could boost future EP/device revenue and competitive share. Read More.
• Neutral Sentiment: BSX appears in a roundup of Wall Street’s favorite long‑term stocks, which highlights bullish analyst price targets but also cautions about optimism in sell‑side forecasts. This may provide upside narrative but is not an immediate catalyst. Read More.
• Negative Sentiment: Multiple law firms and plaintiff‑side notices have announced securities‑fraud lawsuits and lead‑plaintiff deadlines (May 4, 2026) alleging disclosure issues—several filings/alerts from Gross Law Firm, Bernstein Liebhard, Rosen, Levi & Korsinsky, Glancy Prongay Wolke & Rotter, and Faruqi & Faruqi are circulating. The legal overhang raises potential settlement cost, management distraction, and uncertainty that can pressure the stock. Read More. Read More. Read More. Read More. Read More.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.